Riskpilot← Back to searchSign inGet full accessDANOMED ApS
APSActiveCVR 29827400Flæsketorvet 68, 1.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20064 employeeswww.danomed.dk
Revenue 2024
DKK 3M
+11% vs 2023
EBITDA margin
51.4%
+7% vs 2023
Equity ratio
25.0%
Financial strength
Net profit 2024
DKK 1,1M
+9% vs 2023
| Revenue | DKK 3M | +11% |
| EBITDA | DKK 1,6M | +7% |
| Net profit | DKK 1,1M | +9% |
| Total assets | DKK 9,9M | +44% |
| Equity | DKK 2,5M | +43% |
| Employees | 4 | — |
Legal name
DANOMED ApS
CVR number
29827400
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. december 2006
Share capital
DKK 165.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive engrosvirksomhed i sunhedssektoren samt eje aktier og anparter samt anden investering i tilknytning hertil.
Address
Flæsketorvet 68, 1.
Phone
+4570272690
Email
info@danomed.dk
Website
www.danomed.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -40 | 65 | 470 | 736 | 738 | 1.191 | 1.425 | 1.662 | 1.360 | 2.167 | 1.179 | 2.745 | 3.044 |
| Staff expenses | -0 | -24 | -15 | -42 | -404 | -925 | -1.009 | -1.103 | -1.310 | -1.221 | -1.407 | -1.282 | -1.480 |
| EBITDA | -40 | 41 | 455 | 694 | 335 | 266 | 416 | 559 | 50 | 945 | -228 | 1.463 | 1.564 |
| Depreciation & amort. | -0 | -0 | -7 | -14 | -14 | -19 | -25 | -18 | -31 | -45 | -43 | -28 | -21 |
| EBIT | -40 | 41 | 448 | 680 | 321 | 247 | 391 | 541 | 19 | 900 | -271 | 1.435 | 1.543 |
| Net financials | -0 | -2 | -26 | -125 | 103 | -11 | 9 | -34 | -90 | -4 | -84 | -145 | -142 |
| Profit before tax | -40 | 39 | 422 | 555 | 424 | 236 | 399 | 506 | -71 | 896 | -355 | 1.290 | 1.401 |
| Tax | -0 | -0 | 103 | 164 | 70 | 57 | 91 | 114 | -6 | 201 | -65 | 303 | 323 |
| Net profit | -40 | 39 | 319 | 392 | 353 | 179 | 308 | 392 | -65 | 695 | -290 | 986 | 1.078 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.133 | 1.828 | 1.862 | 1.801 | 2.205 | 2.345 | 3.318 | 3.430 | 4.494 | 5.378 | 5.042 | 6.906 | 9.932 |
| Equity | 874 | 913 | 1.232 | 524 | 877 | 1.056 | 1.298 | 891 | 591 | 1.037 | 747 | 1.733 | 2.486 |
| Long-term debt | 0 | 0 | 0 | 492 | 0 | 0 | 0 | 0 | 0 | 70 | 70 | 0 | 0 |
| Short-term debt | 260 | 915 | 628 | 783 | 1.327 | 1.287 | 2.020 | 2.514 | 3.893 | 4.265 | 4.225 | 5.172 | 7.446 |
| Total debt | 260 | 915 | 628 | 1.275 | 1.327 | 1.287 | 2.020 | 2.514 | 3.893 | 4.335 | 4.295 | 5.172 | 7.446 |
EBITDA margin
51.4%
This company
15.8%
Market median
+225% vs market
20122024
Equity ratio
25.0%
This company
38.2%
Market median
-35% vs market
20122024
Return on equity
43.3%
This company
18.4%
Market median
+135% vs market
20122024
Net profit margin
35.4%
This company
8.1%
Market median
+337% vs market
20122024
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20122024
Debt / equity
3.00×
This company
0.62×
Market median
-384% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KG Management | Management | 2017 | — | — |
EA Management | Management | 2025 | — | — |
EB Founder | Founder | 2006 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KGB Invest ApS | Company | 50.0% | 50.0% | 2025 |
Vimira Holding ApS | Company | 15.0% | 15.0% | 2025 |
Ravimi Holding ApS | Company | 15.0% | 15.0% | 2025 |
EBB Holding ApS | Company | 66.7% | 66.7% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KGB Invest ApS
DANOMED ApS Board members of DANOMED ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristian Guldberg Bøje | Management | 0 companies |
| Esben Arnøy Jørgensen | Management | 0 companies |
| Erik Bent Bøje | Founder | 0 companies |